Skip to content

Opening book details…

Can I read Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors on EtoBox?

Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors by Hironobu Hiyoshi; Mamoru Yanagimachi; Masashi Ito; Issei Ohtsuka; Ichiro Yoshida; Takao Saeki; Hiroshi Tanaka is a Medicine article available to read on EtoBox.

What is Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors about?

Squalene synthase (SQS; EC 2.5.1.21) plays an important role in the cholesterol biosynthetic pathway. We discovered ER-28448, 5-(N-[2-butenyl-3-(2-methoxyphenyl)]-N-methylamino)-1, 1-penthylidenebis(phosphonic acid) trisodium salt, as a potent and selective inhibitor of SQS. ER-28448 inhibited SQS in rat liver microsome with an IC(50) value of 3.6 nm. We also prepared ER-27856, the tripivaloyloxymethyl ester prodrug of ER-28448. Although less active than ER-28448 in a liver microsome assay, ER-27856 more potently inhibited cholesterol biosynthesis in rat hepatocytes; and ER-27856 orally inhibited de novo cholesterol biosynthesis in Sprague-Dawley rats, with an ED(50) value of 1.6 mg/kg. In HepG2 cells, ER-27856 upregulated low density lipoprotein receptor activity to 2.1 times that of control. A time-course study indicated that the inhibitory effect of ER-27856 on cholesterol biosynthesis in rats continued for up to 8 h. In a study of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMGRIs), atorvastatin actively suppressed cholesterol biosynthesis for 8 h, whereas the effect of pravastatin and simvastatin diminished at 4 and 8 h, respectively. In rhesus monkeys, 4 days

Who reads Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Hironobu Hiyoshi; Mamoru Yanagimachi; Masashi Ito; Issei Ohtsuka; Ichiro Yoshida; Takao Saeki; Hiroshi Tanaka
Publisher
Elsevier BV
Published
2000
Language
EN
Field
Medicine (Health Sciences)

More by Hironobu Hiyoshi; Mamoru Yanagimachi; Masashi Ito; Issei Ohtsuka; Ichiro Yoshida; Takao Saeki; Hiroshi Tanaka

Browse all works by Hironobu Hiyoshi; Mamoru Yanagimachi; Masashi Ito; Issei Ohtsuka; Ichiro Yoshida; Takao Saeki; Hiroshi Tanaka